Simvastatin treatment does not affect serum vitamin D concentrations in patients with dyslipidemia: A randomized double‑blind placebo‑controlled cross‑over trial

Mazidi, M. and Rokni, H. and Sahebkar, A. H. and Mohammadi, A. and Ghayour-Mobarhan, M. and Ferns, G. A. (2016) Simvastatin treatment does not affect serum vitamin D concentrations in patients with dyslipidemia: A randomized double‑blind placebo‑controlled cross‑over trial. International Journal of Preventive Medicine, 2016 (June).

[img] Text
Simvastatin Treatment Does Not Affect Serum Vitamin D Concentrations in Patients with Dyslipidemia_ A Randomized Double-blind Placebo-controlled Cross-over Trial.pdf

Download (397kB)

Abstract

Background: Hydroxymethylglutaryl‑coenzyme A reductase inhibitors (statins) are antihyperlipidemic drugs with an established efficacy in stabilizing atherosclerotic plaques and preventing atherogenesis and reducing cardiovascular events. The purpose of this study was to determine the effect of simvastatin on serum Vitamin D status in dyslipidemic patients as Vitamin D status has an impact on monocyte/macrophage function and may also contribute to cardiovascular risk. Methods: Selected individuals (n = 102) were treated with simvastatin (40 mg/day), or matching placebo in a randomized, double‑blind, placebo‑controlled, crossover trial. Each treatment period (with simvastatin or placebo) lasted for 30 days and was separated by a 2‑week washout phase. Serum Vitamin D concentration was assessed pre‑ and post‑treatment. Results: Seventy‑seven completed the trial, noncompliance with the study protocol and drug intolerance or relocation were the causes for drop‑out. No significant carry‑over effect was observed for the assessed parameters. There was a reduction in the serum levels of low‑density lipoprotein cholesterol (P < 0.001), total cholesterol (P < 0.001), and triglycerides (P < 0.05). Nevertheless, simvastatin therapy did not significantly affect serum level of high‑density lipoprotein cholesterol and Vitamin D level (P > 0.05). Conclusions: Short‑term treatment with simvastatin (40 mg/day) does not have a significant affect on serum levels of Vitamin D. © 2016 International Journal of Preventive Medicine.

Item Type: Article
Additional Information: Cited By :6 Export Date: 16 February 2020 Correspondence Address: Ghayour-Mobarhan, M.; Cardiovascular Research Center, School of Medicine, Mashhad University of Medical SciencesIran; email: ghayourm@mums.ac.ir
Uncontrolled Keywords: Randomized controlled trial Simvastatin Vitamin D low density lipoprotein cholesterol placebo triacylglycerol adult Article cardiovascular risk clinical protocol controlled study crossover procedure double blind procedure drug effect drug efficacy drug hypersensitivity drug withdrawal dyslipidemia female human macrophage function major clinical study male monocyte outcome assessment treatment duration vitamin blood level
Subjects: QV pharmacology
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib4 lib4
Date Deposited: 01 Mar 2020 09:26
Last Modified: 01 Mar 2020 09:26
URI: http://eprints.mums.ac.ir/id/eprint/13087

Actions (login required)

View Item View Item